ライフサイエンスコーパス: mesenchymal

1 The mesenchymal alveolar niche cell is Wnt responsive, expre

2 tion in primary human fibroblasts as well as mesenchymal and embryonic stem cells for both two- and t

3 he lineage relations and restrictions of the mesenchymal and epithelial cell types in the developing

4 t TAZ but not YAP protein expression in both mesenchymal and epithelial cells.

5 nd T-47D, which morphologically correlate to mesenchymal and epithelial phenotypes, respectively.

6 ypic morphology with characteristics of both mesenchymal and epithelial tumors.

7 mulates the activity of innate immune cells, mesenchymal and hematopoietic stem cells, and insulin-re

8 ne that resulted from consecutive epithelial-mesenchymal and mesenchymal-epithelial transitions (EMT/

9 Mechanistically, miR-128-3p induces mesenchymal and stemness-like properties through downreg

10 plexuses organise around populations of cap mesenchymal and ureteric bud cells in a cyclical, predic

11 iption factor which regulates the epithelial-mesenchymal balance during embryonic development and, if

12 Here, we show that mesenchymal cadherin-11 modulates stromal fibroblast fun

13 the design of therapies for a broad range of mesenchymal cancers.

14 In contrast, tumors arising from more mesenchymal carcinoma cell lines exhibiting EMT markers

15 senescent cholangiocytes promoted quiescent mesenchymal cell activation in a platelet-derived growth

16 Using time-lapse imaging, we find that mesenchymal cell condensation at hair follicles is local

17 iated by immune cell function independent of mesenchymal cell Hox5 family function.

18 their upregulation in metastatic tumors and mesenchymal cell lines is coordinated to that of collage

19 equired in endocardial cells to regulate the mesenchymal cell responses that remodel cardiac cushions

20 ostasis, proliferation of all epithelial and mesenchymal cell types remained low but intermediate cel

21 We review the intestinal mesenchymal cell-specific pathways that regulate these p

22 ar matrix (ECM) constructed by AKAP12+ colon mesenchymal cells (CMCs) generated M2 macrophages by reg

23 RATIONALE: Human cardiac mesenchymal cells (CMSCs) are a therapeutically relevant

24 Mesenchymal cells (MCs) derived from fibrotic lung allog

25 In spiders, a group of BMP secreting mesenchymal cells (the cumulus) functions as an organize

26 mechanism is only present in non-transformed mesenchymal cells as collagen-induced MT1-MMP activation

27 ritical for supporting cell proliferation in mesenchymal cells both in vivo and in vitro beta1 integr

28 . (2017) show that exosomal miRs secreted by mesenchymal cells can regulate epithelial KIT(+) progeni

29 cells in epithelial tissues, are markers of mesenchymal cells in the adult lung.

30 Mesenchymal cells in the intestine comprise a variety of

31 The mesenchymal cells on the other hand, exhibited constitut

32 hat ITGB4(+) cancer stem cell (CSC)-enriched mesenchymal cells reside in an intermediate epithelial/m

33 olling the directed migration of slow-moving mesenchymal cells such as fibroblasts are not well under

34 ctivation of NLRP3 in myeloid cells, but not mesenchymal cells triggers chronic inflammation, which u

35 Exosomes derived from normal fibroblast-like mesenchymal cells were engineered to carry short interfe

36 Treatment of mesenchymal cells with the Cat L inhibitor Z-FY-CHO led

37 Increased HA levels and mesenchymal cells, but not vascular endothelial growth f

38 ive inhibition of RANKL in hematopoietic vs. mesenchymal cells, in conjunction with in situ expressio

39 iferation, migration, and differentiation of mesenchymal cells.

40 -mesenchymal transition and proliferation of mesenchymal cells.

41 secretion by osteoblasts, chondrocytes, and mesenchymal cells.

42 parative processes, and serve as pluripotent mesenchymal cells.

43 ssing phenotypic markers for endothelial and mesenchymal cells.

44 tors are required to activate Hoxd13 in limb mesenchymal cells.

45 prominent clustering of the adjacent dermal mesenchymal cells.

46 p of tumors with a mixture of epithelial and mesenchymal components identifiable by light microscopy.

47 ompaction of the extracellular matrix during mesenchymal condensation is sufficient to drive tissue f

48 These mesenchymal/CSCs have a significantly repressed IFN/STAT

49 epithelial surface cell layer expansion and mesenchymal deep cell intercalations.

50 Insights into the role of mesenchymal dental pulp cells in attenuating dentin reso

51 senchyme, the cells recapitulated epithelial-mesenchymal developing lung interactions.

52 Aberrant mesenchymal-epithelial transition factor (MET) expressio

53 from consecutive epithelial-mesenchymal and mesenchymal-epithelial transitions (EMT/MET) and phenoty

54 entation with the endothelial cell-regulated mesenchymal factors IGFBP2 and IGFBP3.

55 herapeutic strategy for targeting aggressive mesenchymal features of PDAC.

56 nstrate that Sox9 is positively regulated by mesenchymal Fgf10, a process that requires active Erk si

57 ied as a superior and selective biomarker of mesenchymal GBM versus neural, proneural and classical s

58 ylation correlations revealed the epithelial/mesenchymal gene functional category as being influenced

59 Loss of Islet1 results in dysregulation of mesenchymal genes important for morphogenesis of the man

60 at 3D collagen matrix promoted expression of mesenchymal genes including MT1-MMP, which was required

61 se epithelial cell adhesion molecules, while mesenchymal genes involved in cell migration and invasio

62 on disrupt the normal expression of multiple mesenchymal genes that play a key role in airway branchi

63 rognosis and also discriminated infiltrating mesenchymal glioblastoma from poorly motile proneural an

64 Inhibiting Wnt5a in mesenchymal glioblastoma TPC suppressed their infiltrati

65 tially sensitive to EZH2 disruption, whereas mesenchymal GSCs are more sensitive to BMI1 inhibition.

66 l, perivascular GSCs activated EZH2, whereas mesenchymal GSCs in hypoxic regions expressed BMI1 prote

67 hat glioblastomas contain both proneural and mesenchymal GSCs, combined EZH2 and BMI1 targeting prove

68 Epithelial-mesenchymal interactions involve fundamental communicati

69 flammation and injury disrupt the epithelial-mesenchymal interactions required for normal development

70 mobile genetic signals regulating epithelial-mesenchymal interactions.

71 pic heterogeneity in their epithelial versus mesenchymal-like cell states.

72 While such interactions allow single mesenchymal-like cells to spontaneously 'sense' and foll

73 duced in relapse melanomas, which acquired a mesenchymal-like phenotype.

74 served that EpCAM expression is decreased in mesenchymal-like primary cancer specimens in vivo and fo

75 B4), can be used to enable stratification of mesenchymal-like triple-negative breast cancer (TNBC) ce

76 both MDA-MB-468 (basal-like) and MDA-MB-231 (mesenchymal-like) TNBC cell lines in which NO induced CO

77 l to differentiate into multiple cardiac and mesenchymal lineages, with preferential differentiation

78 erogeneous mixture of various epithelial and mesenchymal lineages.

79 d collagen gene expression in ZEB1-activated mesenchymal lung cancer cells.

80 FiVe1 targets the intermediate filament and mesenchymal marker vimentin (VIM) in a mode which promot

81 ansition of mesothelial cells with a gain of mesenchymal markers (vimentin and N-cadherin), whereas e

82 migration and induced the expression of the mesenchymal markers SLUG and ARF6.

83 suppressor, and decreasing the expression of mesenchymal markers.

84 sis, but less responsible for Twist1-induced mesenchymal morphogenesis and expression of certain EMT

85 tumor development subtype (i.e., classical, mesenchymal, neural, proneural).

86 n and localization of Vimentin confirmed the mesenchymal origin of cells and tracked morphological ch

87 tissue and bone sarcomas are malignancies of mesenchymal origin, and more than 50 subtypes are define

88 ety of hematopoietic (e.g. T and B-cell) and mesenchymal (osteoblast lineage, chondrocyte) cell types

89 ng Tag-seq and RNA-seq in female rat Ventral Mesenchymal Pad (VMP) as well as adjacent urethra compri

90 alk between epithelium and their neighboring mesenchymal partners provides new understanding of how d

91 eural profile, and hypoxic regions showing a mesenchymal pattern.

92 invasion, which is accompanied by a loss of mesenchymal phenotype and an increase in cell-cell adhes

93 ed ccRCC cell motility, lung metastasis, and mesenchymal phenotype by regulating key elements in the

94 and other protein features indicating a more mesenchymal phenotype in non-responding tumors.

95 expression of KCNQ1 was lost with increasing mesenchymal phenotype in poorly differentiated CRC cell

96 e and stemness traits upon conversion to the mesenchymal phenotype.

97 ith two different types of hybrid Epithelial/Mesenchymal phenotypes.

98 l cells reside in an intermediate epithelial/mesenchymal phenotypic state.

99 At embryonic day (E) 12.5, the mesenchymal precursor pool began to subdivide into an in

100 ultivariate associations with TTP and CLOVAR mesenchymal profile (worst prognosis).

101 profiling mRNA expression in the bone marrow mesenchymal progenitor cell line ST2, we discover that B

102 covered that the IPF lung harbors fibrogenic mesenchymal progenitor cells (MPCs) that serve as a cell

103 ing in smooth muscle cell differentiation of mesenchymal progenitor cells.

104 Our results demonstrate Tsc2-deficient mesenchymal progenitors cause aberrant morphogenic signa

105 n profile of all known 27 human TRP genes in mesenchymal progenitors cells during white or brown adip

106 A common molecular marker for all osteogenic mesenchymal progenitors has not been identified.

107 Thus Gli1 marks mesenchymal progenitors responsible for both normal bone

108 During development, mesenchymal progenitors tightly regulate the balance bet

109 embryos but is also expressed in multipotent mesenchymal progenitors.

110 Maternal smoke exposure decreases mesenchymal proliferation and modulates Rho-GTPase-depen

111 Palatal defects were caused by increased mesenchymal proliferation leading to early overgrowth of

112 RBB genes with genes encoding epithelial and mesenchymal proteins.

113 both CRTC2 and CRTC3 in stromal cells with a mesenchymal Prx1-Cre transgene also promoted this phenot

114 ntified distinct molecular features in which mesenchymal, Ras-mutant lung cancer is acutely dependent

115 l the presence of Smarcb1-Myc-network-driven mesenchymal reprogramming and independence from MAPK sig

116 and interplay between reaction-diffusion and mesenchymal self-organisation processes in hair follicle

117 her supported by the observation that dental mesenchymal-specific deletion of Evc2 phenocopied the to

118 naling has been shown to directly affect the mesenchymal state and confer it with aggressive phenotyp

119 The mesenchymal state is also associated with cancer stem ce

120 complete transition from an epithelial to a mesenchymal state.

121 RATIONALE: Virtually all mesenchymal stem cell (MSC) studies assume that therapeu

122 suggest that mutations in Evc2 affect dental mesenchymal stem cell homeostasis, which further leads t

123 We evaluated the therapeutic potential of mesenchymal stem cell-conditioned medium (CM-MSC) as an

124 ce has demonstrated that bone marrow-derived mesenchymal stem cells (BMSCs) showed great potential in

125 ve target cells, such as bone marrow-derived mesenchymal stem cells (BMSCs), remains challenging.

126 RATIONALE: Myocardial delivery of human mesenchymal stem cells (hMSCs) is an emerging therapy fo

127 Cartilage grown from human mesenchymal stem cells (hMSCs) is poorly organized and u

128 potential of adipose tissue - derived human mesenchymal stem cells (hMSCs) was evaluated in vitro.

129 MRI, with bone marrow-derived primary human mesenchymal stem cells (hMSCs).

130 Human umbilical cord mesenchymal stem cells (hUC-MSCs), originating in Wharto

131 ofibroblast differentiation of lung resident mesenchymal stem cells (LR-MSCs) and in the lung tissues

132 Mesenchymal stem cells (MSC) are promising therapeutics

133 Bone marrow-derived mesenchymal stem cells (MSC) have been promoted for mult

134 tes suppresses fibrogenesis and desensitizes mesenchymal stem cells (MSCs) against subsequent mechani

135 to evaluate the neuroprotective potential of mesenchymal stem cells (MSCs) against the deleterious im

136 The combination of autologous mesenchymal stem cells (MSCs) and cardiac stem cells (CS

137 uman induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs) and human umbilical vein e

138 Here, mesenchymal stem cells (MSCs) and their nuclei spread in

139 Mouse BM progenitors and human mesenchymal stem cells (MSCs) appeared to contribute in

140 Bone marrow derived mesenchymal stem cells (MSCs) are regularly utilized for

141 study, we investigated the potential role of mesenchymal stem cells (MSCs) derived from human MT in t

142 Adipose-derived (AD) mesenchymal stem cells (MSCs) especially have shown enco

143 Mesenchymal stem cells (MSCs) have multiple properties i

144 the safety and efficacy of allogeneic human mesenchymal stem cells (MSCs) in reducing the time to re

145 EVs) secreted from human bone marrow-derived mesenchymal stem cells (MSCs) on SE-induced adverse chan

146 Mesenchymal stem cells (MSCs) possess immunoregulatory,

147 Mesenchymal stem cells (MSCs) represent promising resour

148 Pericytes are widely believed to function as mesenchymal stem cells (MSCs), multipotent tissue-reside

149 vascular endothelial cells (BMECs) and human mesenchymal stem cells (MSCs).

150 ate a transgenic approach to magnetize human mesenchymal stem cells (MSCs).

151 Human embryonic kidney (HEK) cells and ovine mesenchymal stem cells (oMSCs) were printed at tissue-re

152 Periodontal ligament mesenchymal stem cells (PDLMSCs) are responsible for reg

153 te (HCCS-PDA) were examined by culturing rat mesenchymal stem cells (rMSCs) on HCCS-PDA and HCCS coat

154 Using umbilical cord-derived mesenchymal stem cells (uMSC) from offspring born to nor

155 The viability of human mesenchymal stem cells and osteoblastic SaOS-2 cells was

156 tissue-engineered cultures comprised of rat mesenchymal stem cells dynamically seeded on 85% porous

157 Interestingly, human mesenchymal stem cells exposed in vitro to medium condit

158 We here test whether a new population of mesenchymal stem cells from human gingiva (GMSCs), which

159 ajor factor VIII (FVIII) synthesis site, and mesenchymal stem cells have been shown to control joint

160 oses of allogeneic bone marrow-derived human mesenchymal stem cells identically delivered in patients

161 ges in conventional cell culture systems and mesenchymal stem cells inside biomimetic hydrogels that

162 ve been implicated in the differentiation of mesenchymal stem cells into various cell lineages.

163 The mechanoresponse of human mesenchymal stem cells to e-beam patterned substrates wa

164 itive method was developed to evaluate human mesenchymal stem cells trans-differentiation to endothel

165 n=15) or 100 million (n=15) allogeneic human mesenchymal stem cells via transendocardial injection (0

166 ting of mature white adipocytes, multipotent mesenchymal stem cells, committed progenitor cells, fibr

167 in vitro, compared with bone marrow-derived mesenchymal stem cells, displayed a 55-fold increase in

168 animal due to the presence of epithelial and mesenchymal stem cells-provides a model for the study of

169 s such as dermal fibroblasts and endometrial mesenchymal stem cells.

170 last differentiation and bone formation from mesenchymal stem cells.

171 umber of marker genes previously assigned to mesenchymal stem/progenitor cells, including CD146/Mcam,

172 Umbilical cord-mesenchymal stem/stromal cell therapy decreased nicotina

173 Mesenchymal stem/stromal cells (MSCs) play crucial roles

174 cryopreserved xeno-free human umbilical cord-mesenchymal stem/stromal cells reduce the severity of ro

175 o determine the potential for umbilical cord-mesenchymal stem/stromal cells to reduce E. coli-induced

176 bone formation and the number of bone marrow mesenchymal stem/stromal cells, likely due to decreased

177 on of ZEB1 by TAMs induced Ccl2, Cd74, and a mesenchymal/stem-like phenotype in cancer cells.

178 Human mesenchymal stromal cell (MSC) lines can vary significan

179 in vivo selection of cytokines that improve mesenchymal stromal cell engraftment into the heart both

180 poietic stem cell transplantation (HSCT) and mesenchymal stromal cell therapy have been proposed for

181 In vitro studies have shown that bone marrow mesenchymal stromal cells (BM-MSC) protect AML blasts fr

182 ion (DR) in both ex vivo bone marrow-derived mesenchymal stromal cells (MSC) and in vitro 3T3-L1 prea

183 Mesenchymal stromal cells (MSCs) are a promising candida

184 As mesenchymal stromal cells (MSCs) are continuously expose

185 RATIONALE: Mesenchymal stromal cells (MSCs) are promising therapeut

186 ed with long-term passaged (P10) aging human mesenchymal stromal cells (MSCs) could be used for bone

187 ctor [SCF], ThPO, and IL-6) from bone marrow mesenchymal stromal cells (MSCs) in vitro.

188 erse relationship between a subpopulation of mesenchymal stromal cells and cancer cells in the bone m

189 ave shown convincingly in rodent models that mesenchymal stromal cells can prolong solid organ graft

190 he batch transduction of bone marrow-derived mesenchymal stromal cells ex vivo, followed by intramyoc

191 Mesenchymal stromal cells have emerged as potential cand

192 duces collagen deposition in the bone marrow mesenchymal stromal cells.

193 ether maternal metabolic environment affects mesenchymal stromal/stem cells (MSCs) from umbilical cor

194 Increased protein turnover renders mesenchymal sub-populations highly susceptible to pharma

195 x 1) transcription factor activity in highly mesenchymal SUM159 TNBC cells can repress expression of

196 Here we use mesenchymal system cells (MSC) as a potential substitute

197 previously found that cancer cells in a high mesenchymal therapy-resistant cell state are dependent o

198 While assays to identify mesenchymal TNBC are under development, metaplastic brea

199 Up to 30% of mesenchymal TNBC can be classified histologically as met

200 Using metaplastic TNBC as a surrogate for mesenchymal TNBC, DAT and DAE had notable activity in me

201 al TNBC, DAT and DAE had notable activity in mesenchymal TNBC.

202 surrogate to evaluate potential regimens for mesenchymal TNBC.

203 luripotency marker expression, disruption of mesenchymal to epithelial transition (MET), increased ex

204 ncreatic lineage following proliferation and mesenchymal to epithelial transition (MET).

205 related with induction E-cadherin (CDH1) and mesenchymal-to-epithelial transition (MET) genes.

206 urther comprehensive analysis indicates that mesenchymal-to-epithelial transition is requisite to ini

207 Its knockdown elicited mesenchymal-to-epithelial transition on a molecular and

208 broblastic marker not usually detected after mesenchymal-to-epithelial transition.

209 non-neural ectoderm and regulating specific mesenchymal-to-epithelial transitions in deuterostome an

210 No concomitant epithelial-mesenchymal transformation could, however, be demonstrat

211 ished facilitator of survival adaptation and mesenchymal transformation in glioblastoma (GBM).

212 changes in gene expression and epithelial-to-mesenchymal transformation.

213 es are explored, including direct epithelial-mesenchymal transformations of the lens epithelium or, l

214 riptional programs such as the epithelial-to-mesenchymal transition (EMT) [7, 8].

215 gehog (Hh) pathway is involved in epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC)

216 ted oncogenic functions including epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC)

217 ermore, depletion of DLG5 induced epithelial-mesenchymal transition (EMT) and disrupted epithelial ce

218 part, attributed to increased epithelial-to-mesenchymal transition (EMT) and enhanced tumor cell dis

219 he role of ZEB2 beyond regulating epithelial-mesenchymal transition (EMT) and establish ZEB2 as a nov

220 has been intrinsically linked to epithelial-mesenchymal transition (EMT) and promoting cell survival

221 a, expression is upregulated upon epithelial-mesenchymal transition (EMT) and together with the cytos

222 and in vivo also induced HCC cell epithelial-mesenchymal transition (EMT) as well.

223 e TIC/CSC state and induces an epithelial-to-mesenchymal transition (EMT) by driving expression of th

224 nical Wnt signaling during the epithelial to mesenchymal transition (EMT) from NMP to mesodermal prog

225 sequencing identified a strong epithelial-to-mesenchymal transition (EMT) gene signature in a subset

226 Epithelial-mesenchymal transition (EMT) has been recognized as a ke

227 Reversing epithelial-to-mesenchymal transition (EMT) in cancer cells has been wi

228 , the introduction of inducers of epithelial-mesenchymal transition (EMT) in cystine-independent brea

229 Wnt/beta-catenin signaling and epithelial-to-mesenchymal transition (EMT) in human CRC cell lines of

230 cancer stem cells (CSCs) markers, epithelial-mesenchymal transition (EMT) inducers and basal-enriched

231 Epithelial-mesenchymal transition (EMT) is an important biological

232 Epithelial-to-mesenchymal transition (EMT) is critical for embryonic d

233 Epithelial-mesenchymal transition (EMT) is induced by transforming

234 with qRT-PCR determination of epithelial-to-mesenchymal transition (EMT) markers were performed on h

235 pletion of NatD suppresses the epithelial-to-mesenchymal transition (EMT) of lung cancer cells by dir

236 ed EOC metastasis via inducing epithelial-to-mesenchymal transition (EMT) of ovarian cancer cells in

237 is mediated by proliferation and epithelial mesenchymal transition (EMT) of retinal pigment epitheli

238 ng cancer cells can undergo an epithelial-to-mesenchymal transition (EMT) regulated by various transc

239 phenotype along with enhanced epithelial-to-mesenchymal transition (EMT) signature after USF3 knockd

240 ons, dedifferentiation, and an epithelial to mesenchymal transition (EMT) transcriptional program.

241 re analyzed for markers of the epithelial to mesenchymal transition (EMT) using flow cytometry, immun

242 a underwent a transient fibrotic endothelial-mesenchymal transition (EMT) which was reversed back to

243 cription factors that controls epithelial-to-mesenchymal transition (EMT), a reversible embryonic tra

244 roposed 22-gene network of the Epithelial-to-Mesenchymal Transition (EMT), from which we identified f

245 owing to its role in promoting epithelial-to-mesenchymal transition (EMT), invasiveness and metastasi

246 the contribution of lncRNA to epithelial-to-mesenchymal transition (EMT), which correlates with meta

247 treat, especially the squamous/epithelial-to-mesenchymal transition (EMT)-like subtype.

248 Changes in the expression of epithelial-to-mesenchymal transition (EMT)-related molecules further p

249 with histological evidence of epithelial to mesenchymal transition (EMT).

250 inhibition of genes related to epithelial-to-mesenchymal transition (EMT).

251 ween E- and N-cadherins during epithelial-to-mesenchymal transition (EMT).

252 igration, drug resistance, and epithelial-to-mesenchymal transition (EMT).

253 down, implying the involvement of epithelial-mesenchymal transition (EMT).

254 of ERG expression results in endothelial-to-mesenchymal transition (EndMT) and spontaneous liver fib

255 f EC through a process termed endothelial-to-mesenchymal transition (EndMT).

256 egulated during TGF-beta induced mesothelial-mesenchymal transition (MesoMT).

257 lanced by its ability to suppress epithelial-mesenchymal transition and cell invasion.

258 otecting the endothelium from endothelial-to-mesenchymal transition and consequent liver fibrosis in

259 a-catenin suppressed EGF-mediated epithelial-mesenchymal transition and facilitated epithelial barrie

260 macrophage infiltration, and endothelial-to-mesenchymal transition and improves endothelial Fli1 def

261 culminating in Slug induction, epithelial-to-mesenchymal transition and increased invasion.

262 in vitro and in vivo models of epithelial-to-mesenchymal transition and metastasis, an MMTV-PyMT tran

263 creased HA, which may promote endothelial-to-mesenchymal transition and proliferation of mesenchymal

264 ing acts as a switch to induce epithelial to mesenchymal transition and promote colorectal cancer.

265 -to-disorder transition via an epithelial-to-mesenchymal transition and sort symmetrically into the l

266 Resistin was found to promote epithelial-mesenchymal transition and stemness in breast cancer cel

267 also affected at the level of epithelial-to-mesenchymal transition and the ERK1/2 signaling pathway

268 polymerase chain reaction for epithelial-to-mesenchymal transition and tight junction proteins were

269 were highly adipogenic through an epithelial-mesenchymal transition both in vitro and in vivo.

270 imulated migration, invasion, and epithelial-mesenchymal transition in human prostate cancer cell lin

271 x1 expression and ROS levels associated with mesenchymal transition in these cells.

272 ation, survival, migration and epithelial-to-mesenchymal transition of cancer cells.

273 ing growth factor beta-induced epithelial-to-mesenchymal transition of SKOV-3 cells.

274 on impact on the configuration of epithelial mesenchymal transition pathways in tumor cells.

275 T regulators SNAIL2 and ZEB along with other mesenchymal transition regulators in glioblastoma.

276 dentify subsets with differential epithelial-mesenchymal transition status, carcinoma in situ scores,

277 Epithelial-mesenchymal transition was lower in BEV + RES treated cu

278 ovel functions of PHF8 in EMT (epithelial to mesenchymal transition) and breast cancer development.

279 r cells increased MEK-EMT (MEK-epithelial-to-mesenchymal transition) signaling, transwell invasion an

280 ding to cellular dedifferentiation, enhanced mesenchymal transition, and phenocopying alterations tha

281 broblast differentiation, PMC mesothelial-to-mesenchymal transition, and VEGF-A production.

282 d that ABHD5 knockdown induces epithelial to mesenchymal transition, increasing aerobic glycolysis by

283 e RB/E2F pathway was critical for epithelial-mesenchymal transition, motility, and invasion by cancer

284 ed from bone marrow lineages, endothelial-to-mesenchymal transition, or blood.

285 RIS-B: TGF-beta pathway activity, epithelial-mesenchymal transition, poor prognosis; (iii) CRIS-C: el

286 promotes cellular proliferation, epithelial-mesenchymal transition, stromal reaction, and angiogenes

287 iation, resistance to anoikis, epithelial-to-mesenchymal transition, tumor cell dormancy and escape f

288 ith an increased expression of epithelial-to-mesenchymal transition-related genes.

289 implicating LGR4 in regulation of epithelial-mesenchymal transition.

290 ession of the genes related to epithelial-to-mesenchymal transition.

291 d that it induces reversion of epithelial to mesenchymal transition.

292 T/mTOR or in those involved in epithelial to mesenchymal transition.

293 HYAL2 is important to inhibit endothelial-to-mesenchymal transition.

294 peritoneal fibroblasts, mitigated epithelial-mesenchymal-transition (EMT), as well as enhanced fibrin

295 Mesenchymal transitioned cells are defective in inducibl

296 esident stem/progenitor cells and epithelial-mesenchymal transitions.

297 thelial cell shape and prevent epithelial-to-mesenchymal transitions.

298 mation and FAK/SRC signaling is activated in mesenchymal tumor cells by crosslinked collagen in the E

299 near-complete response to PD-1 blockade in a mesenchymal tumor, we identified PTEN mutations and redu

300 mination by immunotherapy than corresponding mesenchymal tumors.